alendronate has been researched along with Osteoarthritis, Hip in 6 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Osteoarthritis, Hip: Noninflammatory degenerative disease of the hip joint which usually appears in late middle or old age. It is characterized by growth or maturational disturbances in the femoral neck and head, as well as acetabular dysplasia. A dominant symptom is pain on weight-bearing or motion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate treatment by standard dose for osteoporosis showed clinical efficacy for decreasing pain but failed to show preventive effects for structural progression of hip osteoarthritis." | 2.78 | Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial. ( Nishii, T; Shiomi, T; Sugano, N; Tamura, S; Yoshikawa, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yukizawa, Y | 2 |
| Inaba, Y | 3 |
| Kobayashi, N | 3 |
| Choe, H | 1 |
| Kubota, S | 2 |
| Saito, T | 3 |
| Nishii, T | 1 |
| Tamura, S | 1 |
| Shiomi, T | 1 |
| Yoshikawa, H | 1 |
| Sugano, N | 1 |
| Uchiyama, M | 1 |
| Ike, H | 1 |
| Tapaninen, TS | 1 |
| Venesmaa, PK | 1 |
| Jurvelin, JS | 1 |
| Miettinen, HJ | 1 |
| Kröger, HP | 1 |
| Iwamoto, N | 1 |
| Ishida, T | 1 |
| Mehlhorn, AT | 1 |
| Rechl, H | 1 |
| Gradinger, R | 1 |
| Stemberger, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026] | Phase 3 | 70 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| An Open-Label Phase 2 Study of Abaloparatide to Mitigate Distal Femoral Bone Loss Following Total Knee Arthroplasty[NCT04167163] | Phase 4 | 58 participants (Actual) | Interventional | 2020-01-10 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for alendronate and Osteoarthritis, Hip
| Article | Year |
|---|---|
Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Arthroplasty, Replacement, Hip; | 2017 |
Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone | 2013 |
Teriparatide Versus Alendronate for the Preservation of Bone Mineral Density After Total Hip Arthroplasty - A randomized Controlled Trial.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthroplasty, Replacement, Hip; Body Mass Index; Bone Den | 2016 |
Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty - a 5-year follow-up of 16 patients.
Topics: Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; B | 2010 |
A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty.
Topics: Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; F | 2011 |
Alendronate decreases TRACP 5b activity in osteoarthritic bone.
Topics: Acid Phosphatase; Aged; Alendronate; Bone and Bones; Bone Density Conservation Agents; Cell Count; F | 2008 |